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REPORTS
Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist Fibroids (leiomyomas) are the commonest tumours of the uterus. These smooth muscle neoplasms contain more high affinity oestrogen receptors than neighbouring normal uterine muscle' and depend on oestrogen for growth. Oestrogen dependence of fibroids is further reflected in their degeneration and atrophy after the menopause. This suggests that induction of a hypo-oestrogenic state in patients with uterine fibroids would cause shrinkage of these tumours.
Suppression of the pituitary-gonadal axis can be achieved by long term administration of agonist analogues of luteinising hormone releasing hormone (LHRH), and this approach offers the potential for treatment of certain gynaecological disorders.2 Treatment with a LHRH agonist by injection or nasal spray is typically started in the early follicular phase of the menstrual cycle. This initially stimulates, rather than inhibits, oestrogen secretion without attendant progesterone secretion. That is clearly undesirable when suppression of ovarian function is sought. A study by one of us (HMF) in non-human primates showed that infusion of a LHRH agonist from day 21, rather than days 1-3, of the menstrual cycle produced more consistent, rapid, and profound suppression of plasma oestradiol. We report here on a woman whose symptomatic uterine fibroids shrank over several weeks during administration of a LHRH agonist by subcutaneous infusion from day 21 of the cycle.
Case report A 21 year old nulligravid woman presented after two years of intractable dysmenorrhoea. She had been prescribed courses of high dose aspirin, combined oral contraceptives, and mefenamic acid without benefit. A diagnostic laparoscopy was undertaken. On examination under anaesthesia a mass about 5 cm in diameter was palpable to the right of the uterine fundus; the internal uterine cavity was regular, excluding a bicornuate uterus. At laparoscopy the mass was seen to be a uterine fibroid at the right uterotubal junction. Hysterosalpingography showed that the fibroid distorted the filling pattern of the right uterine tube. Fibroid myomectomy was contraindicated because of the site of the tumour with the attendant risk of tubal damage and subsequent infertility.
A trial of treatment with a LHRH agonist (D-Ser(BU')6LHRH (1) (2) (3) (4) (5) (6) (7) (8) (9) 
Comment
Fibroids are the commonest indication for hysterectomy: in Britain in 1979, 15 600 hysterectomies for fibroids were performed (S Cole, personal communication). Typically the patient with symptomatic fibroids is approaching her climacteric, and a course of LHRH agonist may not only eliminate pain or bleeding or both in these women but also, by controlling tumour growth until the natural menopause, remove the need for hysterectomy. Possibly, LHRH agonist treatment of fibroids will, by reducing growth and their blood supply, result in cystic degeneration or necrosis or even lead to spontaneous resolution. Such an effect on the clinical course of these tumours in the younger or infertile patients might render fibroid myomectomy unnecessary or allow a more minor operation, such as carbon dioxide laser coagulation of the remaining focus of the fibroid at laparoscopy. 4 Administration of a LHRH agonist to this patient resulted in a 5000 decrease in fibroid volume within a month. Starting treatment from day 21 of the menstrual cycle avoided the initial unopposed increase in plasma oestradiol concentrations that occurs when the agonist is begun in the follicular phase. Use of an automatic pump to deliver the drug in a near continuous fashion produced a rapid suppression of ovarian function and low plasma oestradiol concentrations. Apart from the expected menstruation, no other vaginal bleeding was observed in our patient, unlike in another study of 
Hepatitis induced by nomifensine
Nomifensine is an antidepressant that is being increasingly prescribed because of its relative lack of cardiovascular and anticholinergic side effects. We report a case of severe hepatitis due to a hypersensitivity reaction to nomifensine.
Case report
A woman aged 67 was admitted to hospital because of depression and difficult social circumstances. She had no history of alcoholism. On examination she looked depressed and had a blood pressure of 220/120 mm Hg but was otherwise normal. All laboratory investigations, including liver function tests, gave normal results. Chest radiography and electrocardiography showed left ventricular hypertrophy. Her hypertension was controlled with nifedipine retard 20 mg twice daily, and she was given nomifensine 25 mg four times a day for depression.
Four weeks later she developed jaundice associated with loss of appetite, general malaise, and muscle pains. She was afebrile, her liver and spleen were not palpable, and there was no ascites. Laboratory investigations showed: haemoglobin concentration 13-2 g/dl, mean cell volume 83 fl, white cell count 7-8x 10xl/1 with 35% eosinophils, erythrocyte sedimentation rate 30 mm in the first hour, total serum bilirubin concentration 250 ptmol/l (14-6 mg/ 100 ml), alkaline phosphatase activity 455 IU/1, and total protein y-glutamyltransferase activity 243 IU/1. Abdominal ultrasound examination showed some gall stones but no dilated bile ducts. Immunological screening, including tests for antinuclear factor, smooth muscle antibodies, and antimitochondrial antibodies, a direct Coombs' test, and tests for hepatitis A and B gave negative results. Serum IgG concentration was 21-2 g/l, but serum concentrations of other immunoglobulins, C3, and C4 were within normal limits.
A percutaneous liver biopsy (figure (top)) showed bridging (periacinar) necrosis, collapsed reticulin framework, central veins linked with portal tracts and each other, pseudolobules, centrilobular cholestasis, and bile plugs. The portal tracts were oedematous and infiltrated with lymphocytes, plasma cells, polymorphonuclear leucocytes, and eosinophils. Bile duct proliferation and acute cholangitis were also seen. There was no evidence of cirrhosis.
Drug induced hepatitis was diagnosed and nifedipine and nomifensine correlated with the drug (J Kranse, Albert Products, personal communication). Nomifensine has been reported to cause hepatic epithelioid cell granulomas that resolved after it was stopped.2 In another case nomifensine produced clinical and histological features of mild hepatitis similar to viral hepatitis, but with no loss of liver architecture, which recurred after reintroduction of the drug.3 In our patient the hepatic injury was more severe. Drug induced hypersensitivity reactions are rare and unpredictable. Nomifensine has been reported to cause immune haemolytic anaemia with renal impairment,4 but this is the first report to our knowledge of hepatitis caused by hypersensitivity to nomifensine. We have reported this case to the Committee on Safety of Medicines.
